CompaniesAdjuvance Technologies

Adjuvance Technologies

defunct

About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct

Clinical Trials (2)

Total Trials

2

As Lead Sponsor

2

As Collaborator

0

Total Enrollment

82

By Phase

PHASE1: 1NA: 1

By Status

TERMINATED: 1SUSPENDED: 1

Clinical Trials Pipeline2 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2018

2019

2020

2021

2022

2023

Today

Hover over trial bars to see details

Recent Trials

NCT04793620Lead Sponsor

Pertussis Acellular Vaccine Adjuvanted With TQL1055

PHASE1Terminated

72 participants

Started: Apr 6, 2021 · Completed: Feb 14, 2022

NCT04094649Lead Sponsor

Acute Study of Effect of Ultrasound Vagus Nerve Stimulation on Glycemia

10 participants

Started: Aug 1, 2019 · Completed: Jul 31, 2022

Funding History (4)

D/A

Nov 22, 2019

D

Sep 24, 2019

D/A

Nov 14, 2016

D

Sep 22, 2015